MX373466B - Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. - Google Patents

Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Info

Publication number
MX373466B
MX373466B MX2016003871A MX2016003871A MX373466B MX 373466 B MX373466 B MX 373466B MX 2016003871 A MX2016003871 A MX 2016003871A MX 2016003871 A MX2016003871 A MX 2016003871A MX 373466 B MX373466 B MX 373466B
Authority
MX
Mexico
Prior art keywords
compositions
proteins
coagulation factor
human recombinant
heterogeneous populations
Prior art date
Application number
MX2016003871A
Other languages
English (en)
Spanish (es)
Other versions
MX2016003871A (es
Inventor
Jason C Rouse
Keith A Johnson
Mary Beth Switzer
Michael Anthony Jankowski
Michael Shamashkin
Penelope Jane Sharpe
Stacey B Weston
Wendy Carol Piacenza
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016003871A publication Critical patent/MX2016003871A/es
Publication of MX373466B publication Critical patent/MX373466B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
MX2016003871A 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. MX373466B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
MX2016003871A MX2016003871A (es) 2016-08-04
MX373466B true MX373466B (es) 2020-05-25

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003871A MX373466B (es) 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Country Status (19)

Country Link
US (3) US9757434B2 (cg-RX-API-DMAC7.html)
EP (1) EP3049434A1 (cg-RX-API-DMAC7.html)
JP (1) JP6429885B2 (cg-RX-API-DMAC7.html)
KR (1) KR101988705B1 (cg-RX-API-DMAC7.html)
CN (2) CN105579468A (cg-RX-API-DMAC7.html)
AR (1) AR097732A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014326257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016005899A8 (cg-RX-API-DMAC7.html)
CA (1) CA2924981C (cg-RX-API-DMAC7.html)
HK (1) HK1218760A1 (cg-RX-API-DMAC7.html)
IL (2) IL244258A0 (cg-RX-API-DMAC7.html)
MX (1) MX373466B (cg-RX-API-DMAC7.html)
MY (1) MY173548A (cg-RX-API-DMAC7.html)
PE (1) PE20160877A1 (cg-RX-API-DMAC7.html)
RU (1) RU2648144C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370751B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201601221XA (cg-RX-API-DMAC7.html)
TW (1) TWI631134B (cg-RX-API-DMAC7.html)
WO (1) WO2015044836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
PE20190661A1 (es) * 2016-06-17 2019-05-08 Portola Pharm Inc Preparacion de derivados del factor xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
JP2008509688A (ja) * 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンk依存性ポリペプチド
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
DK2915564T3 (da) * 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ, インコーポレイテッド 第Xa因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EA201291482A1 (ru) * 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
AU2012315516B2 (en) 2011-09-30 2017-05-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CA2928762A1 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
MX375355B (es) 2014-01-24 2025-03-04 Pfizer Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Also Published As

Publication number Publication date
BR112016005899A8 (pt) 2018-02-06
KR20160044034A (ko) 2016-04-22
CN105579468A (zh) 2016-05-11
US20150182604A1 (en) 2015-07-02
TWI631134B (zh) 2018-08-01
AU2014326257A1 (en) 2016-03-10
IL244258A0 (en) 2016-04-21
BR112016005899A2 (pt) 2017-09-26
TW201524996A (zh) 2015-07-01
JP6429885B2 (ja) 2018-11-28
AU2014326257B2 (en) 2017-08-10
KR101988705B1 (ko) 2019-06-12
EP3049434A1 (en) 2016-08-03
CA2924981A1 (en) 2015-04-02
WO2015044836A1 (en) 2015-04-02
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
RU2648144C2 (ru) 2018-03-22
IL279396A (en) 2021-01-31
PE20160877A1 (es) 2016-09-11
CA2924981C (en) 2020-03-31
MY173548A (en) 2020-02-04
RU2016108608A (ru) 2017-10-26
CN112195169A (zh) 2021-01-08
SG11201601221XA (en) 2016-04-28
US20210106658A1 (en) 2021-04-15
AR097732A1 (es) 2016-04-13
HK1218760A1 (zh) 2017-03-10
JP2016535071A (ja) 2016-11-10
US9757434B2 (en) 2017-09-12
US10660946B2 (en) 2020-05-26
SA516370751B1 (ar) 2018-04-05

Similar Documents

Publication Publication Date Title
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
EP2547355A4 (en) TFPI INHIBITORS AND METHODS OF USE THEREOF
EP2760879A4 (en) PROTEIN-CONTAINING LUBRICANTS, THEIR PREPARATION AND USE
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
EP2889308A4 (en) CONEPOXIN PEPTIDE OF THE ALPHA O-SUPERFAMILY, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL231930A0 (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
IL279396A (en) Preparations containing heterogeneous populations of recombinant human coagulation factor XA proteins
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EP3359962A4 (en) BLOOD PREPARATION AND PROFILING
MX387579B (es) Polipéptidos del factor vii de acción corta.
MX2016004702A (es) Polipeptidos del factor vii de coagulacion.
EP3752113C0 (en) SURGICAL GAUZE
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
WO2013109190A3 (en) Cho-gmt recombinant protein expression
BR112014018709A8 (pt) Composições e efetores de beta-arrestina e métodos de uso dos mesmos
PH12016500509B1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
MX361222B (es) Composiciones sellantes.
WO2014115087A3 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
MX385558B (es) Péptidos y métodos de uso.
FR3049867B1 (fr) Composition hemostatique et cicatrisante
TH149189B (th) แอนติโดทของสารต้านการแข็งตัวของเลือด

Legal Events

Date Code Title Description
FG Grant or registration